timothy sykes logo

Stock News

RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 2/25/2026, 5:04 pm ET 2/25/2026, 5:04 pm ET | 4 min 4 min read
RXRX Showcased at NVIDIA’s GTC Conference as AI Labs Collaborate Thumbnail

Recursion Pharmaceuticals Inc.’s stocks have been trading up by 7.37 percent, highlighting positive market sentiment.

Candlestick Chart

Live Update At 17:03:27 EST: On Wednesday, February 25, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 7.37%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Recursion Pharmaceuticals has recently been in the spotlight, thanks to various strategic moves stirring both excitement and curiosity in the biotech world. Their revenue streams, however, paint a picture that’s not all rosy. Despite an annual revenue of around $58.49M, profitability remains a struggle, with stark numbers reflecting significant net losses on the income statements. The gross margin stands at -59.5%, and they reported a net loss of $162.25M. But, the company still forges ahead with innovative strategies, notably harnessing AI to revamp drug discovery approaches.

The company holds a promising financial strength with a current ratio of 4.6, indicating good short-term liquidity. Their total assets amount to $1.4B, most being cash-rich with more than $659M in cash and cash equivalents.

Market Reactions to Nvidia Conference Appearance and Institutional Investments

Recursion Pharmaceuticals is no stranger to groundbreaking endeavors, especially when it comes to the world of artificial intelligence coupled with drug discovery. At the recent NVIDIA GTC conference, HighRes Biosolutions is set to unveil their partnership with Recursion, focusing on AI-enabled drug discovery labs. This partnership emphasizes the active exploration and growth within the field and aims to stir market interest, reflecting in Recursion’s current market position.

More Breaking News

Adding fuel to Recursion’s expansive narrative is the backing by ARK Investment. With Cathie Wood at the helm, ARK’s acquisition of 1.2M shares demonstrates institutional confidence. Such investments often function as a barometer, indicating future confidence in a company’s technological advancements and potential profitability.

Investor Confidence on the Rise

The narrative that wraps Recursion is one of potential and promise. The biotech company, aside from its AI endeavors, has caught the eye of larger institutional players due to its recent advancements. Positive outcomes from their Phase 1b/2 TUPELO trial, reflecting progress in treating genetic disorders like familial adenomatous polyposis, bolster investor confidence.

Institutional investors, recognizing the value in AI-driven biology platforms, are keeping their eyes fixed on Recursion. The platform’s scalability potential is seen as a major driver, especially in an era where precision medicine promises to revolutionize healthcare. Such institutional attention not only boosts stockholder morale but also signifies a rounding endorsement of Recursion’s strategic market position.

Conclusion

In summary, Recursion Pharmaceuticals stands at a crucial juncture. With strides in AI-enabled drug research and notable institutional backing, the company’s direction towards addressing significant medical challenges seems promising. Despite financial hurdles presented through persistent net losses, these strategic engagements and technology-driven approaches forecast a potentially transformative future for RXRX. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” This trading wisdom resonates with the approach needed as trader confidence gains momentum, suggesting strategic decisions that might edge closer to financial sustainability while continuing to tackle healthcare challenges on a grander scale.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”